论文部分内容阅读
目的评价依达拉奉治疗急性缺血性脑出血的疗效与安全性。方法 2011年2月—2013年2月选择急性缺血性脑出血患者186例,随机分为对照组90例和治疗组96例,对照组给予20%甘露醇125 ml快速静脉滴注,肠溶阿司匹林100 mg/次,每日1次,丹参16 ml(5%葡萄糖注射液250 ml稀释)静脉滴注,每日1次等常规治疗,治疗组在常规治疗的同时给予依达拉奉30 mg/次(生理盐水100 ml稀释),每日2次,静脉滴注,两组均治疗14 d。分别于治疗前、治疗后14 d按照《中国脑出血临床神经功能缺损程度评分量表》进行评分,治疗后30 d按改良Rankin量表评分,并比较两组不良反应。结果神经功能缺损程度评分对照组和治疗组总有效率分别为51.11%和86.46%,两组比较差异有统计学意义(P<0.05)。Rankin评分对照组和治疗组总有效率分别为60.00%和83.33%,两组比较差异有统计学意义(P<0.05)。治疗组血转氨酶轻微升高2例,尿素氮升高1例,给予相应治疗,不影响治疗结果。结论依达拉奉对急性缺血性脑出血患者安全有效,值得推广。
Objective To evaluate the efficacy and safety of edaravone in the treatment of acute ischemic cerebral hemorrhage. Methods From February 2011 to February 2013, 186 patients with acute ischemic cerebral hemorrhage were randomly divided into control group (n = 90) and treatment group (n = 96). The control group was given 125% rapid intravenous infusion of mannitol Aspirin 100 mg / time, once daily, Salvia 16 ml (5% glucose injection 250 ml diluted) intravenous infusion, once a day and other conventional treatment, the treatment group were given conventional edaravone 30 mg / Times (saline diluted 100 ml), 2 times a day, intravenous infusion, both groups were treated for 14 days. The patients were scored on the 14th day after treatment according to the Scale of Clinical Neurological Deficiency of Chinese Intracerebral Hemorrhage. The modified Rankin scale was scored 30 days after treatment and adverse reactions were compared between the two groups. Results The score of neurological impairment was 51.11% in the control group and 86.46% in the treatment group. There was significant difference between the two groups (P <0.05). Rankin score of the control group and the treatment group were 60.00% and 83.33%, respectively, with significant difference between the two groups (P <0.05). Serum transaminase slightly elevated in treatment group 2 cases, 1 case of elevated urea nitrogen, given the appropriate treatment, does not affect the treatment outcome. Conclusion Edaravone is safe and effective for patients with acute ischemic cerebral hemorrhage and is worth promoting.